{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:19:44Z","timestamp":1778631584708,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19kk0305009"],"award-info":[{"award-number":["JP19kk0305009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","award":["JP21tm0124005"],"award-info":[{"award-number":["JP21tm0124005"]}],"id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","award":["JP17km0105001"],"award-info":[{"award-number":["JP17km0105001"]}],"id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP22ama121019"],"award-info":[{"award-number":["JP22ama121019"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bcp.2024.116515","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T22:27:00Z","timestamp":1725056820000},"page":"116515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals"],"prefix":"10.1016","volume":"229","author":[{"given":"Shuki","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Hishinuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Kijogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Nakayoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Tadaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kumondai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116515_b0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/00498250701449431","article-title":"Involvement of human cytochrome P450 2B6 in the \u03c9- and 4-hydroxylation of the anesthetic agent propofol","volume":"37","author":"Murayama","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2024.116515_b0015","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0b013e32835d9ab0","article-title":"Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state","volume":"23","author":"Benowitz","year":"2013","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.bcp.2024.116515_b0025","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2024.116515_b0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","volume":"110","author":"Desta","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00008571-200111000-00007","article-title":"Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19","volume":"11","author":"Hoffman","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bcp.2024.116515_b0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00008571-199906000-00004","article-title":"Human CYP2B6: expression, inducibility and catalytic activities","volume":"9","author":"Gervot","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bcp.2024.116515_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0050","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2024.116515_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2024.116515_b0060","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0065","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116515_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2024.116515_b0075","first-page":"520","article-title":"PharmGKB summary: very important pharmacogene information for CYP2B6, Pharmacogenet","volume":"20","author":"Thorn","year":"2010","journal-title":"Genomics"},{"key":"10.1016\/j.bcp.2024.116515_b0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2024.116515_b0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31083\/ph.2022.2382","article-title":"Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico","volume":"77","author":"Ort\u00edz-Rodr\u00edguez","year":"2022","journal-title":"Pharmazie"},{"key":"10.1016\/j.bcp.2024.116515_b0095","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/jac\/dkz329","article-title":"Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations","volume":"74","author":"Ayuso","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2024.116515_b0100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116515_b0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41397-019-0112-2","article-title":"Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults","volume":"20","author":"Cheng","year":"2020","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.bcp.2024.116515_b0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.bcp.2024.116515_b0115","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jce.13032","article-title":"Efavirenz inhibits the human ether-A-Go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers","volume":"27","author":"Abdelhady","year":"2016","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.bcp.2024.116515_b0120","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"German Competence Network for HIV\/AIDS Coordinators, Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2024.116515_b0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116515_b0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2133\/dmpk.DMPK-13-NT-092","article-title":"Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece","volume":"29","author":"Mastrogianni","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2024.116515_b0135","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2133\/dmpk.DMPK-11-RG-039","article-title":"Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age","volume":"26","author":"Kansaku","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2024.116515_b0140","first-page":"13","article-title":"The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on propofol pharmacokinetics in children, Pharmgenomics","volume":"13","author":"Pavlovic","year":"2020","journal-title":"Pers. Med."},{"key":"10.1016\/j.bcp.2024.116515_b0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.biopsych.2006.10.005","article-title":"CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial","volume":"62","author":"Lee","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116515_b0150","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jcph.878","article-title":"Cytochrome P450 genetic variations can predict mRNA expression, cyclophosphamide 4-hydroxylation, and treatment outcomes in Chinese patients with non-Hodgkin\u2019s lymphoma","volume":"57","author":"Shu","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0155","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1111\/bcp.15393","article-title":"Methadone pharmacogenetics in vitro and in vivo: metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition","volume":"88","author":"Wang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00228-011-1132-2","article-title":"Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia","volume":"68","author":"Loryan","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00540-018-2470-3","article-title":"Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics","volume":"32","author":"Kanaya","year":"2018","journal-title":"J. Anesth."},{"key":"10.1016\/j.bcp.2024.116515_b0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40246-018-0157-3","article-title":"Integrating rare genetic variants into pharmacogenetic drug response predictions","volume":"12","author":"Ingelman-Sundberg","year":"2018","journal-title":"Hum. Genom."},{"key":"10.1016\/j.bcp.2024.116515_b0175","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bcp.2018.09.010","article-title":"Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation","volume":"156","author":"Watanabe","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0180","article-title":"Functional characterization of 21 rare allelic CYP1A2 variants identified in a population of 4773 Japanese individuals by assessing phenacetin O-Deethylation","volume":"11","author":"Kumondai","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bcp.2024.116515_b0185","article-title":"Functional assessment of 12 rare allelic CYP2C9 variants identified in a population of 4773 Japanese individuals","volume":"11","author":"Kumondai","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bcp.2024.116515_b0190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/dmd.120.000261","article-title":"Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2032-hydroxylation and testosterone 6\u03b2-hydroxylation","volume":"49","author":"Kumondai","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116515_b0195","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1124\/dmd.123.001389","article-title":"Functional characterization of 29 cytochrome P450 4F2 variants identified in a population of 8380 Japanese subjects and assessment of arachidonic acid omega-hydroxylation","volume":"51","author":"Sato","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116515_b0200","doi-asserted-by":"crossref","first-page":"D536","DOI":"10.1093\/nar\/gkaa1034","article-title":"jMorp updates in: 2020 large enhancement of multi-omics data resources on the general Japanese population","volume":"49","author":"Tadaka","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2024.116515_b0205","doi-asserted-by":"crossref","first-page":"D622","DOI":"10.1093\/nar\/gkad978","article-title":"jMorp: Japanese Multi-Omics Reference Panel update report 2023","volume":"52","author":"Tadaka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2024.116515_b0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2133\/dmpk.19.155","article-title":"Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals","volume":"19","author":"Hiratsuka","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2024.116515_b0215","doi-asserted-by":"crossref","first-page":"14193","DOI":"10.1038\/s41598-020-71035-5","article-title":"Heterologous expression of high-activity cytochrome P450 in mammalian cells","volume":"10","author":"Kumondai","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116515_b0220","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116515_b0225","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nprot.2009.121","article-title":"Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase","volume":"4","author":"Guengerich","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2024.116515_b0230","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0090-9556(24)14931-8","article-title":"Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences","volume":"27","author":"Court","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116515_b0235","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/mol.109.062570","article-title":"Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution","volume":"77","author":"Gay","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116515_b0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bcp.2024.116515_b0245","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cplett.2003.12.039","article-title":"Molecular dynamics simulations of water and biomolecules with a Monte Carlo constant pressure algorithm","volume":"384","author":"\u00c5qvist","year":"2004","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.bcp.2024.116515_b0250","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/bip.360320508","article-title":"Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide","volume":"32","author":"Loncharich","year":"1992","journal-title":"Biopolymers"},{"key":"10.1016\/j.bcp.2024.116515_b0255","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory. Comput."},{"key":"10.1016\/j.bcp.2024.116515_b0260","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2024.116515_b0265","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/jcc.20221","article-title":"New AMBER force field parameters of heme iron for cytochrome P450s determined by quantum chemical calculations of simplified models","volume":"26","author":"Oda","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2024.116515_b0270","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N \u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bcp.2024.116515_b0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.bcp.2024.116515_b0280","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of Molecular Dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory. Comput."},{"key":"10.1016\/j.bcp.2024.116515_b0285","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1248\/bpb.31.1552","article-title":"Determination of ligand-binding sites on proteins using long-range hydrophobic potential","volume":"31","author":"Yamaotsu","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2024.116515_b0290","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/jcc.21299","article-title":"Evaluation of the searching abilities of HBOP and HBSITE for binding pocket detection","volume":"30","author":"Oda","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2024.116515_b0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.fpc.0000114759.08559.51","article-title":"Discovery of new potentially defective alleles of human CYP2C9","volume":"14","author":"Blaisdell","year":"2004","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.bcp.2024.116515_b0300","doi-asserted-by":"crossref","first-page":"8700","DOI":"10.1021\/bi100911q","article-title":"Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding","volume":"49","author":"Roberts","year":"2010","journal-title":"Biochemistry."},{"key":"10.1016\/j.bcp.2024.116515_b0305","doi-asserted-by":"crossref","first-page":"e96789","DOI":"10.1371\/journal.pone.0096789","article-title":"Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation","volume":"9","author":"Kobayashi","year":"2014","journal-title":"PLOS ONE."},{"key":"10.1016\/j.bcp.2024.116515_b0310","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jcc.23680","article-title":"Including ligand-induced protein flexibility into protein tunnel prediction","volume":"35","author":"Kingsley","year":"2014","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2024.116515_b0315","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jinorgbio.2004.02.007","article-title":"Sudarko, A survey of active site access channels in cytochromes P450","volume":"98","author":"Wade","year":"2004","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2024.116515_b0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.bbagen.2006.07.005","article-title":"The ins and outs of cytochrome P450s","volume":"1770","author":"Cojocaru","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2024.116515_b0325","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/bab.1074","article-title":"Conformational diversity and ligand tunnels of mammalian cytochrome P450s","volume":"60","author":"Yu","year":"2013","journal-title":"Biotechnol. Appl. Biochem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:58:29Z","timestamp":1778630309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224004982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":65,"alternative-id":["S0006295224004982"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116515","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116515"}}